Quick Answer
ZEVRA THERAPEUTICS, INC. reported Earnings Per Share Diluted of $1.35 per share for the year ending 2025.
- ZEVRA THERAPEUTICS, INC. showed an increase of +159.2% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from ZEVRA THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2020 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2015: $2.45 (loss) per share | Q2 2016: $0.58 (loss) per share | Q2 2017: $0.44 (loss) per share | Q2 2018: $0.91 (loss) per share | Q3 2018: $0.94 (loss) per share | Q2 2019: $0.33 (loss) per share | Q3 2019: $0.06 per share | Q1 2020: $1.92 (loss) per share | Q2 2020: $0.21 per share | Q3 2020: $0.68 (loss) per share | Q1 2021: $2.49 (loss) per share | Q2 2021: $0.40 (loss) per share | Q3 2021: $0.06 (loss) per share | Q2 2024: $0.48 (loss) per share | Q3 2024: $0.69 (loss) per share | Q2 2025: $1.21 per share | Q3 2025: $0.01 (loss) per share.
- Over the full 4 years of available data (2020 to 2025), ZEVRA THERAPEUTICS, INC.'s Earnings Per Share Diluted has grown by 142.1%.
- Historical annual values: Fiscal year 2025: $1.35 per share | Fiscal year 2024: $2.28 (loss) per share | Fiscal year 2021: $2.11 (loss) per share | Fiscal year 2020: $3.21 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: